Key Findings
Precision BioSciences has announced the commencement of patient dosing in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, an in vivo gene editing therapy targeting Duchenne muscular dystrophy (DMD). This innovative approach utilizes the company’s proprietary ARCUS® genome editing platform to enable the endogenous production of a near full-length, functional dystrophin protein, applicable to up to 60% of DMD patients. Initial safety data from this trial are expected to be reported by year-end.
Technical/Clinical Details
Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder caused by mutations in the dystrophin gene, leading to the absence of functional dystrophin protein and progressive muscle degeneration. PBGENE-DMD is an in vivo gene editing therapy that employs Precision BioSciences’ unique ARCUS® nuclease platform. ARCUS® is a genome editing system that combines a guide RNA with a DNA-cleaving enzyme to precisely target specific DNA sequences. This therapy aims to correct the reading frame shift by specifically excising the region corresponding to exons 45 through 55 of the dystrophin gene. This ‘exon skipping by excision’ strategy is designed to enable the production of a truncated but functional dystrophin protein, often referred to as ‘minidystrophin’ or ‘microdystrophin.’ The presence of a functional dystrophin protein is expected to restore muscle cell stability and slow the progression of the disease. This exon excision approach is potentially applicable to up to 60% of DMD patients, addressing a significant portion of the patient population currently underserved by existing therapies. The Phase 1/2 FUNCTION-DMD clinical trial will evaluate the safety and tolerability in dose-escalation cohorts, while also collecting preliminary efficacy data through biomarkers such as serum dystrophin protein expression levels and motor function assessments. The first patient dosing was conducted under strict safety protocols.
Background & Context
DMD currently has limited curative options and often leads to premature death. While exon-skipping antisense oligonucleotide therapies have received approval, their efficacy is often modest, and they require frequent administration. Gene therapy, by directly correcting or replacing the dystrophin gene, represents a more fundamental approach and holds significant promise. Precision BioSciences’ ARCUS® platform is distinguished by its unique mechanism and high specificity compared to other genome editing technologies (e.g., CRISPR), making it particularly noteworthy for therapeutic applications in monogenic disorders like DMD. The initiation of patient dosing marks a critical milestone in DMD gene therapy development.
Strategic Significance & Outlook
The upcoming initial safety data for PBGENE-DMD, expected by year-end, could have a profound impact on DMD patient care. Accumulating efficacy data would position it as a groundbreaking therapy capable of slowing DMD progression and improving patients’ muscle function and quality of life, potentially leading to regulatory approval. This technology holds the promise of broader application to other inherited muscle diseases and is expected to serve as a precedent, further advancing in vivo gene editing technologies.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments